HC or M&A IB Group for HF

I was curious which makes more sense in this context. I know that coverage groups aren’t rly getting super deep exposure to the point where HFs solely take ppl in a coverage group. However, as someone who is primarily interested in HC markets and investing, would it make more sense to stay in this coverage team? Or would being in a product group still be more valuable (and possibly give more optionality, since I’ve heard many biotech focused funds or MMHFs with bio arms favor MDs/PhDs anyway).

Would love color on this, since I’m not very familiar with how HF recruiting works for this sector specifically.